Axelar announces positive interim results in Phase I/II study
(Thomson Reuters ONE) -
STOCKHOLM, SWEDEN, APRIL 6, 2011. Axelar AB, a Karolinska Development portfolio
company, today announces positive results from the completed first part of the
combined Phase I/II clinical trial, evaluating AXL1717 as a new treatment for
solid tumors. The study has successfully reached its primary endpoint,
identifying the recommended Phase II dose as well as provided evidence that
AXL1717 is safe and tolerable. Furthermore, data also supports Axelar's strategy
to target AXL1717 in patients with squamous non-small cell lung cancer. Results
will be presented later this year.
In the ongoing study, AXL1717 has been tested in total of more than 45 patients.
The now completed first part of the study with a total of 35 patients, consisted
of a single-day dosing as well as a multi dosing part. The study has been
amended to a Phase II design. AXL1717 is now tested for 28 days BID (twice daily
dosing) in two cycles with 14 days interval in order to confirm the Phase II
regimens and explore the possible anti-tumor effects. A Phase II program is
expected to start late 2011.
Dr. Johan Harmenberg, CEO of Axelar:
"The successful completion of the first part of the Phase I/II study is an
important milestone for Axelar. It also supports our beliefs that AXL1717 has
the potential to become a new and effective treatment in cancer therapy. We are
optimistic that the coming Phase II program will show clinical benefit to cancer
patients."
Dr. Torbjørn Bjerke, CEO at Karolinska Development:
"Karolinska Development is excited about the progress that Axelar has made with
AXL1717. Data from this study looks promising for AXL1717 as a new treatment for
cancer. Karolinska Development is the largest owner with 45 percent of the
company and Axelar is therefore an important company within Karolinska
Development's broad oncology portfolio, and we look forward to the coming Phase
II program."
For further information, please contact:
Johan Harmenberg, CEO Axelar AB
Phone: +46 (0) 705 14 54 53, e-mail:johan.harmenberg(at)axelar.se
Torbjørn Bjerke, CEO Karolinska Development AB
Phone: +46 (0) 727 44 41 23, e-mail:torbjorn.bjerke(at)karolinskadevelopment.com
TO THE EDITORS
About Axelar
Axelar AB is a Swedish biotech company founded in 2003. The company is
developing insulin-like growth factor 1 (IGF-1) receptor inhibitors for
treatment of cancer and other diseases. Axelar is part of the Karolinska
Development portfolio of companies.www.axelar.se
About AXL1717
Axelar's lead compound, AXL1717 provides a novel treatment regimen for a wide
range of cancers. AXL1717 is the first targeted oral small-molecule IGF-1
receptor inhibitor with no effect on the closely related insulin receptor.
AXL1717 is presently undergoing phase I/II clinical trials and the compound
combines a superior preclinical efficacy against numerous tumors with an
excellent tolerability profile. Most tumor cells are dependent on the IGF-1
receptor signal pathway and the IGF-1 receptor is therefore regarded as a
promising target for cancer therapy. To date, there are no IGF-1 receptor
inhibitor drugs on the market.
About Karolinska Development
Karolinska Development aims to create value for investors, patients, and
researchers by developing innovations from world class research into products
that can be sold or out-licensed with high returns. The business model is to:
SELECT the most commercially attractive medical innovations; DEVELOP these to
the stage where the greatest return on investment can be achieved; and
COMMERCIALIZE the innovations through the sale of companies or out licensing of
products. This will result in upfront payments, milestone payments and
royalties.
An exclusive deal flow agreement with Karolinska Institutet Innovations AB,
along with other cooperation agreements with leading Nordic universities,
delivers a continuous flow of innovations.
Karolinska Development's flexible exit strategy enables projects to be exited at
whichever stage of development offers the greatest return on investment, usually
after Phase II clinical trials have indicated the desired pharmaceutical effect
on patients - this being an important value enhancing step.
Today, the portfolio consists of over 40 projects at various stages, from
concept development to Phase II clinical trials, twelve projects are in clinical
trials with six in Phase II. The portfolio is particularly strong in the areas
of cancer, dermatology, inflammation, cardiovascular disease, women's health and
diseases that affect the central nervous system. www.karolinskadevelopment.com
News Release as PDF:
http://hugin.info/143071/R/1503702/438616.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Karolinska Development AB (publ) via Thomson Reuters ONE
[HUG#1503702]
Unternehmensinformation / Kurzprofil:
Datum: 06.04.2011 - 07:30 Uhr
Sprache: Deutsch
News-ID 53195
Anzahl Zeichen: 5766
contact information:
Town:
Solna
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 126 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Axelar announces positive interim results in Phase I/II study"
steht unter der journalistisch-redaktionellen Verantwortung von
Karolinska Development AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
